News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

SUBSCRIBE

SUBSCRIBE

News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

Search Query

Search Results

Looking for jobs? Search jobs

17,797 Results

Type

Article (3048)
Company Profile (4)
Press Release (14745)

Section

Business (7040)
Career Advice (96)
Deals (984)
Drug Delivery (10)
Drug Development (2638)
Employer Resources (13)
FDA (587)
Job Trends (622)
News (11015)
Policy (1037)

Tag

Date

Today (7)
Last 7 days (21)
Last 30 days (67)
Last 365 days (850)
2024 (738)
2023 (818)
2022 (2045)
2021 (1817)
2020 (1403)
2019 (1200)
2018 (965)
2017 (1221)
2016 (911)
2015 (985)
2014 (735)
2013 (602)
2012 (636)
2011 (611)
2010 (623)

Location

Africa (51)
Asia (1290)
Australia (179)
California (44)
Canada (23)
China (5)
Connecticut (4)
Delaware (5)
Europe (4437)
Illinois (4)
Massachusetts (48)
New Jersey (16)
New York (6)
North Carolina (14)
Northern California (26)
Pennsylvania (8)
South America (51)
Southern California (12)

Filters

Type

Article (3048)
Company Profile (4)
Press Release (14745)

Section

Business (7040)
Career Advice (96)
Deals (984)
Drug Delivery (10)
Drug Development (2638)
Employer Resources (13)
FDA (587)
Job Trends (622)
News (11015)
Policy (1037)

Tag

Date

Today (7)
Last 7 days (21)
Last 30 days (67)
Last 365 days (850)
2024 (738)
2023 (818)
2022 (2045)
2021 (1817)
2020 (1403)
2019 (1200)
2018 (965)
2017 (1221)
2016 (911)
2015 (985)
2014 (735)
2013 (602)
2012 (636)
2011 (611)
2010 (623)

Location

Africa (51)
Asia (1290)
Australia (179)
California (44)
Canada (23)
China (5)
Connecticut (4)
Delaware (5)
Europe (4437)
Illinois (4)
Massachusetts (48)
New Jersey (16)
New York (6)
North Carolina (14)
Northern California (26)
Pennsylvania (8)
South America (51)
Southern California (12)

17,797 Results for "novartis".

Sort By

Earnings

Novartis Gets Q3 Beat on Strong Cosentyx Sales, But Pluvicto Disappoints

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well as the robust performances of Kesimpta and Kisqali.

October 29, 2024
·
2 min read
·
Tristan Manalac
Approvals

Novartis Secures First-Line CML Expansion for Scemblix, Projects $3B in Peak Sales

Scemblix was granted accelerated approval by the FDA for the treatment of certain patients newly diagnosed with chronic myeloid leukemia. The expanded indication increases the eligible patient population by approximately four times, according to Novartis.

October 30, 2024
·
2 min read
·
Tristan Manalac
Drug pricing

NJ Court Tosses Novartis’ Lawsuit Against Drug Negotiation Program in Latest Setback for Big Pharma

With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies that have failed in their legal challenges to the Inflation Reduction Act.

October 21, 2024
·
2 min read
·
Tristan Manalac
Approvals

Novartis Pushes Kisqali Into Earlier Stages of Breast Cancer, Nearly Doubles Eligible Patient Population

The FDA’s approval of Kisqali in combination with an aromatase inhibitor allows Novartis to target patients with earlier breast cancer who are at risk of recurrence.

September 18, 2024
·
2 min read
·
Tristan Manalac
Business

Novartis, Versant Launch RNA Kidney Medicines—Focused Borealis

Looking to build on the success of Chinook Therapeutics, founded by Versant in 2019 and acquired by Novartis last year, the companies on Thursday launched Borealis Biosciences with $150 million in funding to develop RNA therapeutics for kidney diseases.

August 22, 2024
·
2 min read
·
Kate Goodwin
Cardiovascular disease

Novartis Plots Leqvio Expansion After Lowering Cholesterol in Phase III Study

Armed with new late-stage data on reducing low-density lipoprotein cholesterol, Novartis is positioning its siRNA therapy Leqvio as a preventive treatment for atherosclerotic cardiovascular disease.

August 29, 2024
·
2 min read
·
Tristan Manalac
Legal

Novartis Loses Court Case to Block Entresto Generics After FDA Denies Petition

On the heels of the FDA’s denial of its petition, a Delaware district court on Monday handed Novartis another loss in its efforts to keep the market free of Entresto copycats.

August 13, 2024
·
2 min read
·
Tristan Manalac
Deals

MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders

MorphoSys AG announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024.

June 20, 2024
·
10 min read
Earnings

Despite Layoff Announcements, Novartis Beats Q2 Expectations

Novartis’ second-quarter earnings, announced Thursday, show strong performance of its blockbuster drugs, prompting the company to raise its year-end guidance.

July 18, 2024
·
2 min read
·
Tyler Patchen
Collaboration

Novartis, Dren Bio Ink Potential $3B Deal for Anti-Myeloid Bispecific Antibodies for Cancer

Novartis continues its dealmaking spree with a bet on Dren Bio’s Targeted Myeloid Engager and Phagocytosis platform to develop bispecific antibodies in oncology.

July 25, 2024
·
2 min read
·
Tristan Manalac

1 of 1,780

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

Explore
About
More

© 1985 - 2024 BioSpace.com. All rights reserved.

twitter
instagram
facebook
linkedin